SCHEMBL1383596

SCHEMBL1383596

COc1cc(CCc2cnc(Nc3cc(Cl)cc(C(F)(F)F)c3)c3ccccc23)ccn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 6/20 0.38
▸ FLT1 P17948 2/20 0.38
▸ RAPGEF4 Q8WZA2 1/20 0.36
▸ FYN P06241 1/20 0.35
▸ GSK3B P49841 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ ZAP70 P43403 1/20 0.35
▸ SYK P43405 1/20 0.35
▸ EGFR P00533 3/20 0.34
▸ ABCG2 Q9UNQ0 2/20 0.34
▸ TNF P01375 1/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ HDAC1 Q13547 1/20 0.34
▸ HDAC2 Q92769 1/20 0.34
▸ HDAC6 Q9UBN7 1/20 0.34
▸ RAF1 P04049 1/20 0.34
▸ BRAF P15056 1/20 0.34
▸ BUB1 O43683 1/20 0.34
▸ TRPA1 O75762 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383615 0.88 KDR (0.48) KDRFLT1FYNGSK3BMAPT
SCHEMBL1385761 0.86 KDR (0.39) KDRFLT1RAPGEF4EGFRABCG2
SCHEMBL1385235 0.82 NAMPT (0.46) KDRFLT1MAPTHDAC3HDAC1
SCHEMBL1383679 0.81 RAPGEF4 (0.38) KDRFLT1RAPGEF4EGFRABCG2
SCHEMBL1385899 0.75 EGFR (0.36) KDRFLT1MAPTEGFRABCG2
SCHEMBL4825615 0.75 LOXL2 (0.46) TRPA1
SCHEMBL1386811 0.75 KDR (0.44) KDRFLT1EGFRABCG2
SCHEMBL1383073 0.75 CCNK (0.35) KDRFLT1MAPTEGFRABCG2
SCHEMBL1382827 0.74 EGFR (0.48) KDRFLT1SYKEGFRABCG2
SCHEMBL1383487 0.72 KDR (0.48) KDRFLT1MAPTEGFRABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4837864-B2 — — 2011-12-14 — — JP claimed
US-7323474-B2 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase NOVARTIS AG (CH) 2008-01-29 — — US claimed
EP-1254138-B1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2005-05-11 — — EP claimed
US-20040209894-A1 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase BOLD GUIDO 2004-10-21 — — US claimed
US-6706731-B2 WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2004-03-16 — — US claimed
US-20030158409-A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase NOVARTIS AG (CH) 2003-08-21 — — US claimed
EP-1254138-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE Novartis AG (CH) 2002-11-06 — — EP claimed
WO-2001058899-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2001-08-16 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209894-A1 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase FLT1, FLT4, KDR KDR 3/4885FLT1 1/4885RAPGEF4 1351/4885
US-20030158409-A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase FLT1, FLT4, KDR KDR 3/4885FLT1 1/4885RAPGEF4 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback